Navigation Links
Novo Nordisk Ranks Supersector Leader in the 2007 Dow Jones Sustainability Indexes
Date:9/24/2007

PRINCETON, N.J., Sept. 24 /PRNewswire-FirstCall/ -- Novo Nordisk, a world leader in diabetes care, announced that effective today, the company is listed in the Dow Jones Sustainability World Index (DJSI World) as best-in-class in the healthcare industry -- one of 18 global supersectors analyzed.

The latest global analysis of corporate sustainability leadership was based on a thorough analysis of companies' economic, environmental and social performance, assessing issues including corporate governance, risk management, branding, climate change, supply chain standards and labor practices.

The report concludes "Novo Nordisk is the leading company in terms of sustainability in the pharmaceutical industry. Sustainability is an integral part of its corporate strategy and business organization."

The report continues, "Novo Nordisk is particularly strong in the social dimension where it achieved the industry top ratings in human capital development, corporate citizenship/philanthropy, and social reporting." The company's responsible sourcing, environmental management, bioethics and climate strategy also achieve high scores.

"This honor provides us further encouragement for operating our business according to our Triple Bottom Line philosophy -- a company that can be economically vital, as well as socially and environmentally responsible," said Martin Sorters, president, Novo Nordisk in the United States.

"Our passion for changing diabetes is supported by an understanding that sustainability in business is not just possible but necessary. By putting the patient at the center of all we do -- from providing the best therapies to patients and advocating our employees' volunteerism with patient groups and at diabetes camps to our environmental stewardship through water conservation efforts and our climate change strategy -- we strive to be successful and responsible."

The indexes, which currently comprise USD$5.6 billion assets under ma
'/>"/>

SOURCE Novo Nordisk
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Ontario Ranks Highest in Free Bird Flu Vaccination Rates
2. Imbalance In Gender Ratio Addressed By Religious Leaders
3. Religious Leaders condemn determination of sex in hospitals
4. Need For Social Churning Emphasized In CMC Meet On ‘Leadership In Healthcare
5. North-Eastern Leaders Of India Meet To Discuss HIV Problems
6. Cheerleaders run high risk of injury-US study
7. Muslim Leaders’ Help Sought To Discourage Smokin
8. India needs dental health leadership, says expert
9. Freedom Fighter And Orissa Congress Leader Dies Of Chest Pain
10. Religious Leaders Come In The Way Of Euthanasia
11. Learn From a Leader: Smitherman shares a personal story about his battle with drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... May 05, 2015 AxoGen, Inc. ... on the $1.6 billion peripheral nerve repair market, reported ... ended March 31, 2015 compared to $3.14 million in ... adoption of our proprietary portfolio of nerve repair products ... AxoGuard® Nerve Protector – and our solid sales execution ...
(Date:5/5/2015)... May 05, 2015 The 2015 Crystal Ball, ... to benefit their global research, outreach and patient advocacy programs. ... and awards ceremony that attracted hundreds of supporters. , The ... discovery of the hepatitis B virus (HBV) by Dr. Baruch ... the Nobel Prize in Medicine for his discovery of the ...
(Date:5/5/2015)... Fla. (PRWEB) May 05, 2015 Baptist ... the Commission on Cancer (CoC) of the American College ... cancer program must meet more than 30 Commission on ... through a survey process, and maintain levels of excellence ... , When patients choose to seek care locally at ...
(Date:5/5/2015)... May 05, 2015 " QuickPick Travel ” ... Report, which takes a look small, medium, and large businesses ... for NewsWatch and a business expert, conducted the business review ... to plan up to three weeks of vacation for free. ... and friends, and explore the world. And when people are ...
(Date:5/5/2015)... ProTexting, LLC – a premier SMS ... Engagement Campaigns and other Mobile solutions, introduces e-mail integration ... leverage the power of Mobile Marketing to expand their ... addresses into the Constant Contact Platform. , ProTexting CEO, ... trend of multi-channel marketing would become more prominent in ...
Breaking Medicine News(10 mins):Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 2Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 3Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 4Health News:Hepatitis B Foundation Marks 50th Anniversary of HBV Discovery at its Crystal Ball Gala 2Health News:Hepatitis B Foundation Marks 50th Anniversary of HBV Discovery at its Crystal Ball Gala 3Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 2Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 3Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 4Health News:A Platform to Plan the Perfect Vacation was Featured on NewsWatch Television 2Health News:ProTexting SMS Mobile Marketing platform integrates with Constant Contact 2Health News:ProTexting SMS Mobile Marketing platform integrates with Constant Contact 3
... People are more likely to disapprove of and avoid substance ... a new study. Participants were presented with six fictitious ... alcohol or drugs, smoked, or was obese. "Specifically, participants ... to marry into their family, be friends, socialize, work on ...
... from Loyola University Chicago Stritch School of Medicine ... selected for prestigious Schweitzer Fellowships. Michelle Leahy, Ray ... to design and implement innovative, yearlong projects to ... well-being. Named in honor of famed humanitarian ...
... Cardinal Bernardin Cancer Center has received an Outstanding Achievement ... College of Surgeons. The award is given to ... rating in each of seven standards. The centers were ... areas of cancer program activity: cancer committee leadership, cancer ...
... -- Receiving emotional support and acceptance from parents benefits ... a new study shows. About three-quarters of lesbian, ... in Massachusetts said they had revealed their sexual orientation ... years old. About two-thirds said their parents were supportive. ...
... Reporter , FRIDAY, April 13 (HealthDay News) -- Obese and ... more radiation than people of normal weight, researchers say. ... is needed to scan their bodies, a radiation specialist said. ... size, increase the power of the X-rays and the quantity ...
... April 13 (HealthDay News) -- The physical architecture of intelligence ... brain injury patients to conduct their research. The findings ... general intelligence and specific skills such as memory and the ... War veterans who had highly localized brain damage caused by ...
Cached Medicine News:Health News:Loyola Stritch, Niehoff students receive prestigious Schweitzer Fellowships 2Health News:Gay Adults Rejected by Parents Have Worse Health, Study Finds 2Health News:CT Scans Deliver More Radiation to Obese People: Study 2Health News:Researchers Map Brain Regions Linked to Intelligence 2
(Date:5/5/2015)... FORT WORTH, Texas , May 5, 2015 /PRNewswire/ ... market was valued at $94.9 million in 2014, and ... at a CAGR of 7.8% from 2014 to 2019. ... Ophthalmology Glaucoma Surgery Device Market for an analysis of ... tables and figures. http://www.micromarketmonitor.com/market/north-america-glaucoma-surgery-devices-8830146604.html ...
(Date:5/5/2015)... ST. LOUIS and NIJMEGEN, ... -- EndoStim, a medical device company developing lower ... disease (GERD) announced long-term, 3-year, positive safety and ... of reflux symptoms of both heartburn and regurgitation ... 24-hour esophageal pH test) with near-complete elimination of ...
(Date:5/5/2015)... LONG BEACH, Calif. and ST. ... with diabetes, high blood pressure or high cholesterol may ... part of performance-based networks, according to early results of ... Express Scripts (NASDAQ: ESRX ). "Pharmacists ... professionals and their frequent interactions with our members presents ...
Breaking Medicine Technology:North America Ophthalmology Glaucoma Surgery Device Market is Expected to Reach $138.3 Million by 2019, at a CAGR of 7.8% From 2014 to 2019 2North America Ophthalmology Glaucoma Surgery Device Market is Expected to Reach $138.3 Million by 2019, at a CAGR of 7.8% From 2014 to 2019 3Excellent three year results of EndoStim therapy for severe reflux disease presented at the SAGES Annual Meeting in Nashville. 2Excellent three year results of EndoStim therapy for severe reflux disease presented at the SAGES Annual Meeting in Nashville. 3SCAN Health Plan, Express Scripts' Quality Network Improves Medicare Beneficiary Health 2SCAN Health Plan, Express Scripts' Quality Network Improves Medicare Beneficiary Health 3SCAN Health Plan, Express Scripts' Quality Network Improves Medicare Beneficiary Health 4
... Data from a pivotal trial suggests that ofatumumab has ... treatments , , ... and Genmab A/S (OMX: GEN) announced today positive results ... (ofatumumab) in the treatment of refractory chronic lymphocytic leukemia ...
... Alexion Pharmaceuticals,Inc. (Nasdaq: ALXN ) ... open-label,registration study examining Soliris(R) (eculizumab) treatment of ... pre-specified,primary efficacy endpoint of change in hemolysis ... Key secondary endpoints including fatigue,(P<0.001) and transfusions/anemia ...
Cached Medicine Technology:Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 2Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 3Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 4Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 5Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 6Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 7Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 8Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 9Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH 2Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH 3Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH 4Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH 5Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH 6Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH 7Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH 8
... An enzyme-linked immunosorbent assay ... detection of IgG-class antibodies to ... test is intended to be ... the diagnosis of gastrointestinal disorders, ...
... assurance reagent in assays detecting IgG and IgM ... IgM), IgG and IgM antibodies to rubella virus ... antibodies to cytomegalovirus (CMV IgG and IgM), and ... types 1 and 2 (HSV-1 IgG, HSV-1 IgM, ...
... a safe, non-surgical process that uses ... skin and reverse the signs of ... to cause collagen contraction while preserving ... addition, Titan can stimulate long-term collagen ...
... XLTEK lets you choose how to configure ... of the study to be performed we ... to your budget and clinical needs. How do ... we listen. The result? Kortex. The system that ...
Medicine Products: